Trial results for the Phase 2 study (NCT05052723) investigating cabozantinib and pembrolizumab in metastatic pancreatic adenocarcinoma were posted on ClinicalTrials.gov on 2025-11-19. The study, which enrolled 21 participants, reported 1 participant with a partial response to therapy.
Background
The study, titled "Cabozantinib and Pembrolizumab in Metastatic Pancreas," aimed to evaluate the combination of cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.
Trial design
The study (NCT05052723) was a Phase 2 trial with an enrollment of 21 participants. It investigated the combination of cabozantinib and pembrolizumab in patients with Pancreatic Cancer.
Key results
The trial reported the following outcomes for the combination of cabozantinib and pembrolizumab:
- For "Progression-free Survival," 2 Participants were reported.
- For "Number of Participants With Response to Therapy," 1 Participant was reported.
- For "Number of Participants With Complete Response," 0 Participants were reported.
- For "Number of Participants With Partial Response," 1 Participant was reported.
- For "Overall Participant Survival Rate," 2 Participants were reported.
What this means
The results from this Phase 2 study provide initial data on the efficacy of cabozantinib and pembrolizumab in a small cohort of patients with metastatic pancreatic adenocarcinoma. The reported outcomes, including 1 partial response and 2 participants with progression-free survival and overall survival, offer preliminary insights into the activity of this combination therapy in a challenging disease setting. Further research would be needed to fully understand the potential role of this combination.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT05052723, titled "Cabozantinib and Pembrolizumab in Metastatic Pancreas," were posted on 2025-11-19 on clinicaltrials.gov.